JP7014808B2 - Ａｍｐａ受容体増強薬 - Google Patents

Ａｍｐａ受容体増強薬 Download PDF

Info

Publication number
JP7014808B2
JP7014808B2 JP2019543832A JP2019543832A JP7014808B2 JP 7014808 B2 JP7014808 B2 JP 7014808B2 JP 2019543832 A JP2019543832 A JP 2019543832A JP 2019543832 A JP2019543832 A JP 2019543832A JP 7014808 B2 JP7014808 B2 JP 7014808B2
Authority
JP
Japan
Prior art keywords
alkyl
compounds
compound
compound according
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019543832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507592A (ja
JP2020507592A5 (OSRAM
Inventor
サイモン・ワード
ポール・ベスウィック
ルイス・ペニコット
トリスタン・ルイヨン
Original Assignee
ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド filed Critical ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド
Publication of JP2020507592A publication Critical patent/JP2020507592A/ja
Publication of JP2020507592A5 publication Critical patent/JP2020507592A5/ja
Application granted granted Critical
Publication of JP7014808B2 publication Critical patent/JP7014808B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2019543832A 2017-02-10 2018-02-09 Ａｍｐａ受容体増強薬 Active JP7014808B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1702221.1 2017-02-10
GBGB1702221.1A GB201702221D0 (en) 2017-02-10 2017-02-10 Compounds
PCT/GB2018/050370 WO2018146486A1 (en) 2017-02-10 2018-02-09 Ampa receptor potentiators

Publications (3)

Publication Number Publication Date
JP2020507592A JP2020507592A (ja) 2020-03-12
JP2020507592A5 JP2020507592A5 (OSRAM) 2021-03-18
JP7014808B2 true JP7014808B2 (ja) 2022-02-01

Family

ID=58462168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019543832A Active JP7014808B2 (ja) 2017-02-10 2018-02-09 Ａｍｐａ受容体増強薬

Country Status (12)

Country Link
US (1) US11186567B2 (OSRAM)
EP (1) EP3580213B1 (OSRAM)
JP (1) JP7014808B2 (OSRAM)
KR (1) KR102665887B1 (OSRAM)
CN (1) CN110520418B (OSRAM)
AU (1) AU2018218307C1 (OSRAM)
ES (1) ES2974824T3 (OSRAM)
GB (1) GB201702221D0 (OSRAM)
MX (1) MX2019009537A (OSRAM)
NZ (1) NZ755747A (OSRAM)
RU (1) RU2019126574A (OSRAM)
WO (1) WO2018146486A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds
WO2024255822A1 (zh) * 2023-06-15 2024-12-19 上海魁特迪生物科技有限公司 Dir结合剂及其用途
CN121652294A (zh) * 2026-02-06 2026-03-13 首都医科大学宣武医院 一种用于检测抗ampar1抗体的融合蛋白及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148836A1 (en) 2007-06-08 2008-12-11 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
JP2009541404A (ja) 2006-07-04 2009-11-26 ナームローゼ・フエンノートチヤツプ・オルガノン Ａｍｐａ増強剤としてのピラゾールアルカンアミド置換チオフェン
JP2011503139A (ja) 2007-11-13 2011-01-27 ナームローゼ・フエンノートチヤツプ・オルガノン 複素環式誘導体
JP2011523656A (ja) 2008-06-06 2011-08-18 ナームローゼ・フエンノートチヤツプ・オルガノン Ａｍｐａ受容体モジュレーターとしてのインダン誘導体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
ES2320973T3 (es) 2000-06-12 2009-06-01 EISAI R&D MANAGEMENT CO., LTD. Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos.
AU2003302027A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
WO2006109056A1 (en) 2005-04-12 2006-10-19 Vicore Pharma Ab New tricyclic angiotensin ii agonists
CA2646585A1 (en) 2006-03-20 2007-09-27 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
EA016415B1 (ru) 2006-04-24 2012-04-30 Эли Лилли Энд Компани Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
DE602007013450D1 (de) * 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
JP5470557B2 (ja) 2007-07-26 2014-04-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成
EP2195303A4 (en) 2007-09-20 2011-07-20 Cortex Pharma Inc 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE AND 3-SUBSTITUTED 1,3-PYRIMIDIONE FOR INCREASING GLUTAMATERGIC SYNAPTIC REACTIONS
GB0721094D0 (en) 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
JP5696037B2 (ja) 2008-05-01 2015-04-08 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
BRPI1014583B1 (pt) 2009-06-26 2020-03-31 Pfizer, Inc. Sulfonamidas heterocíclicas e composições farmacêuticas
WO2011132051A2 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Tricycle compounds as phosphodiesterase-10 inhibitors
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541404A (ja) 2006-07-04 2009-11-26 ナームローゼ・フエンノートチヤツプ・オルガノン Ａｍｐａ増強剤としてのピラゾールアルカンアミド置換チオフェン
WO2008148836A1 (en) 2007-06-08 2008-12-11 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
JP2011503139A (ja) 2007-11-13 2011-01-27 ナームローゼ・フエンノートチヤツプ・オルガノン 複素環式誘導体
JP2011523656A (ja) 2008-06-06 2011-08-18 ナームローゼ・フエンノートチヤツプ・オルガノン Ａｍｐａ受容体モジュレーターとしてのインダン誘導体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACS Medicinal Chemistry Letters，2015年02月11日，6，392-396
Bioorganic & Medicinal Chemistry Letters，2010年，20，5753-5756
Bioorganic & Medicinal Chemistry Letters，2010年，20，6072-6075
Bioorganic & Medicinal Chemistry Letters，2011年，21，805-811
British Journal of Pharmacology，2010年，160，181-190

Also Published As

Publication number Publication date
AU2018218307C1 (en) 2022-06-23
ES2974824T3 (es) 2024-07-01
CN110520418B (zh) 2022-08-16
JP2020507592A (ja) 2020-03-12
US11186567B2 (en) 2021-11-30
MX2019009537A (es) 2019-10-04
WO2018146486A1 (en) 2018-08-16
AU2018218307B2 (en) 2022-02-24
NZ755747A (en) 2022-02-25
CA3051647A1 (en) 2018-08-16
EP3580213B1 (en) 2024-03-27
RU2019126574A (ru) 2021-03-10
CN110520418A (zh) 2019-11-29
BR112019016603A2 (pt) 2020-03-31
KR20190117549A (ko) 2019-10-16
AU2018218307A1 (en) 2019-08-15
EP3580213A1 (en) 2019-12-18
KR102665887B1 (ko) 2024-05-10
EP3580213C0 (en) 2024-03-27
US20210139463A1 (en) 2021-05-13
RU2019126574A3 (OSRAM) 2021-03-29
GB201702221D0 (en) 2017-03-29

Similar Documents

Publication Publication Date Title
JP7014808B2 (ja) Ａｍｐａ受容体増強薬
US20250375432A1 (en) Compounds that modulates ampa receptor function
KR20130122531A (ko) Ｍｇｌｕｒ５ 양성 알로스테릭 조절물로서 치환된 ６­메틸니코틴아미드
US10538523B2 (en) 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
CA3051647C (en) Ampa receptor potentiators
HK40044378B (en) Compounds that modulates ampa receptor function
HK40044378A (en) Compounds that modulates ampa receptor function
BR112019016603B1 (pt) Composto, uso deste e uma formulação farmacéutica
CN101084215B (zh) 作为glyt1抑制剂的哌啶和氮杂环丁烷衍生物
WO2016020784A1 (en) N-acylpyrrolidine ether tropomyosin-related kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210203

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220120

R150 Certificate of patent or registration of utility model

Ref document number: 7014808

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350